Kimia Biosciences Ltd

Kimia Biosciences Limited informed the BSE Limited that it has received a certificate from Beetal Financial & Computer Services Private Limited, its Registrar and Share Transfer Agent (RTA), confirming compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.

Kimia Biosciences Limited announced that its members approved the appointment and reappointment of directors at the 33rd Annual General Meeting held on September 28, 2026. Mr. Amulya Kumar Nayak, Ms. Reema Goyal, and Mr. Avinash Prabhat were appointed as directors, while Mr. Sameer Goel was reappointed as director. Mr. Sameer Goel holds 74.94% shareholding in Kimia Biosciences Limited.

Kimia Biosciences Limited informed the BSE Limited that the trading window for equity shares will be closed from October 1, 2026, until 48 hours after the declaration of the company’s unaudited financial results for the quarter and half-year ended September 30, 2026, in accordance with SEBI regulations.

Kimia Biosciences Limited has set the cut-off date for determining voting eligibility for its 33rd Annual General Meeting (AGM) as September 21, 2026, with remote e-voting commencing on September 25, 2026, and concluding on September 27, 2026. The AGM is scheduled for September 28, 2026, at 3:00 P.M., and will be facilitated through National Securities Depository Limited (NSDL).

Kimia Biosciences Limited announced the re-appointment of Sameer Goel as director, liable to retire by rotation, and the appointment of Amulya Kumar Nayak as a Non-Executive, Non-Independent Director, and Reema Goyal and Avinash Prabhat as Non-Executive Independent Directors, all subject to member approval at the company’s 33rd Annual General Meeting. The board also approved remuneration for Cost Auditors M/s Mahesh Singh & Co., and authorized seeking member approval for increasing borrowing limits, creating mortgages, and making loans, guarantees, and securities, as per the Companies Act, 2013. Additionally, the company approved the 33rd AGM, scheduled for September 28, 2026, with a cut-off date for e-voting on September 21, 2026.

Kimia Bioscienes Limited will hold a board meeting on August 10, 2026, to consider and approve the unaudited financial results for the first quarter ended June 30, 2026, according to a regulatory filing with the BSE Limited. The trading window for equity shares of the company for designated persons and their immediate relatives has been closed from July 1, 2026, until 48 hours after the financial results are declared.

Kimia Biosciences Limited announced the appointment of M/s Mahesh Singh & Co. as Cost Auditor for the financial year 2026-27, and M/s Chaudhry & Associates as Internal Auditor for the same period. The company also disclosed the discontinuance of M/s M & Co. as Secretarial Auditor, effective August 1, 2026, and the appointment of M/s Maya Sharma and Associates as Secretarial Auditor for the financial years 2025-26 and 2026-27.

Kimia Biosciences Limited announced the appointment of M/s Mahesh Singh & Co. as Cost Auditor for the financial year 2026-27, and M/s Chaudhry & Associates as Internal Auditor for the same period. The company also disclosed the discontinuance of M/s M & Co. as Secretarial Auditor, effective August 1, 2026, and the appointment of M/s Maya Sharma and Associates as Secretarial Auditor for the financial years 2025-26 and 2026-27.

Net profit of Kimia Biosciences declined 81.41% to Rs 0.37 crore in the quarter ended March 2026 as against Rs 1.99 crore during the previous quarter ended March 2025. Sales declined 28.87% to Rs 27.20 crore in the quarter ended March 2026 as against Rs 38.24 crore during the previous quarter ended March 2025. For the full year,net profit declined 22.68% to Rs 7.43 crore in the year ended March 2026 as against Rs 9.61 crore during the previous year ended March 2025. Sales declined 3.40% to Rs 114.88 crore in the year ended March 2026 as against Rs 118.92 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales27.2038.24 -29 114.88118.92 -3 OPM %9.7821.39 -12.4217.03 - PBDT2.927.22 -60 12.3717.01 -27 PBT1.766.34 -72 8.4613.63 -38 NP0.371.99 -81 7.439.61 -23 Powered by Capital Market - Live

Kimia Biosciences will hold a meeting of the Board of Directors of the Company on 29 May 2026.